Literature DB >> 33658609

Retinoblastoma tumor cell proliferation is negatively associated with an immune gene expression signature and increased immune cells.

Aaron L Sarver1, Chencheng Xie2, Megan J Riddle2, Colleen L Forster3, Xiaohong Wang2, Huarui Lu2, Wyatt Wagner2, Jakub Tolar2, Timothy C Hallstrom4.   

Abstract

This study focuses on gene expression differences between early retinal states that ultimately lead to normal development, late onset retinoblastoma, or rapid bilateral retinoblastoma tumors. The late-onset and early-onset retinoblastoma tumor cells are remarkably similar to normally proliferating retinal progenitor cells, but they fail to properly express differentiation markers associated with normal development. Further, early-onset retinoblastoma tumor cells express a robust immune gene expression signature followed by accumulation of dendritic, monocyte, macrophage, and T-lymphocyte cells in the retinoblastoma tumors. This characteristic was not shared by either normal retinae or late-onset retinoblastomas. Comparison of our data with other human and mouse retinoblastoma tumor gene expression significantly confirmed, that the immune signature is present in tumors from each species. Strikingly, we observed that the immune signature in both mouse and human tumors was most highly evident in those with the lowest proliferative capacity. We directly assessed this relationship in human retinoblastoma tumors by co-analyzing proliferation and immune cell recruitment by immunohistochemistry, uncovering a significant inverse relationship between increased immune-cell infiltration in tumors and reduced tumor cell proliferation. Directly inhibiting proliferation with a PI3K/mTOR inhibitor significantly increased the number of CD45+ immune cells in the retina. This work establishes an in vivo model for the rapid recruitment of immune cells to tumorigenic neural tissue.

Entities:  

Mesh:

Year:  2021        PMID: 33658609     DOI: 10.1038/s41374-021-00573-x

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  80 in total

Review 1.  The E2F transcriptional network: old acquaintances with new faces.

Authors:  Desssislava K Dimova; Nicholas J Dyson
Journal:  Oncogene       Date:  2005-04-18       Impact factor: 9.867

Review 2.  Conserved functions of the pRB and E2F families.

Authors:  Sander van den Heuvel; Nicholas J Dyson
Journal:  Nat Rev Mol Cell Biol       Date:  2008-09       Impact factor: 94.444

Review 3.  Toward an understanding of the functional complexity of the E2F and retinoblastoma families.

Authors:  J R Nevins
Journal:  Cell Growth Differ       Date:  1998-08

4.  Distinct roles for E2F proteins in cell growth control and apoptosis.

Authors:  J DeGregori; G Leone; A Miron; L Jakoi; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

5.  Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.

Authors:  Diane E Rushlow; Berber M Mol; Jennifer Y Kennett; Stephanie Yee; Sanja Pajovic; Brigitte L Thériault; Nadia L Prigoda-Lee; Clarellen Spencer; Helen Dimaras; Timothy W Corson; Renée Pang; Christine Massey; Roseline Godbout; Zhe Jiang; Eldad Zacksenhaus; Katherine Paton; Annette C Moll; Claude Houdayer; Anthony Raizis; William Halliday; Wan L Lam; Paul C Boutros; Dietmar Lohmann; Josephine C Dorsman; Brenda L Gallie
Journal:  Lancet Oncol       Date:  2013-03-13       Impact factor: 41.316

6.  Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.

Authors:  Julien Sage; Abigail L Miller; Pedro A Pérez-Mancera; Julianne M Wysocki; Tyler Jacks
Journal:  Nature       Date:  2003-07-10       Impact factor: 49.962

Review 7.  Retinoblastoma.

Authors:  Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie
Journal:  Nat Rev Dis Primers       Date:  2015-08-27       Impact factor: 52.329

Review 8.  Non-canonical functions of the RB protein in cancer.

Authors:  Frederick A Dick; David W Goodrich; Julien Sage; Nicholas J Dyson
Journal:  Nat Rev Cancer       Date:  2018-07       Impact factor: 60.716

Review 9.  RB1: a prototype tumor suppressor and an enigma.

Authors:  Nicholas J Dyson
Journal:  Genes Dev       Date:  2016-07-01       Impact factor: 11.361

Review 10.  Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine.

Authors:  Michael A Dyer
Journal:  Trends Mol Med       Date:  2016-08-23       Impact factor: 11.951

View more
  4 in total

1.  UHRF2 regulates cell cycle, epigenetics and gene expression to control the timing of retinal progenitor and ganglion cell differentiation.

Authors:  Xiaohong Wang; Aaron L Sarver; Qiyuan Han; Christopher L Seiler; Chencheng Xie; Huarui Lu; Colleen L Forster; Natalia Y Tretyakova; Timothy C Hallstrom
Journal:  Development       Date:  2022-03-14       Impact factor: 6.862

2.  Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.

Authors:  Zijun Y Xu-Monette; Li Wei; Xiaosheng Fang; Qingyan Au; Harry Nunns; Hua You; Máté Nagy; Alexandar Tzankov; Feng Zhu; Carlo Visco; Govind Bhagat; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Eric D Hsi; Fredrick B Hagemeister; Xiaoping Sun; Xin Han; Heounjeong Go; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Benjamin M Parsons; J Han van Krieken; Miguel A Piris; Jane N Winter; Yong Li; Bing Xu; Maher Albitar; Ken H Young
Journal:  Clin Cancer Res       Date:  2022-03-01       Impact factor: 13.801

3.  Comprehensive Analysis of the Immune Cell Infiltration Landscape and Immune-Related Methylation in Retinoblastoma.

Authors:  Peiyao Mao; Yinchen Shen; Xun Xu; Jiawei Zhong
Journal:  Front Genet       Date:  2022-05-18       Impact factor: 4.772

4.  Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.

Authors:  Lynn M Heltemes-Harris; Gregory K Hubbard; Rebecca S LaRue; Sarah A Munro; Rendong Yang; Christine M Henzler; Timothy K Starr; Aaron L Sarver; Steven M Kornblau; Michael A Farrar
Journal:  Oncogene       Date:  2021-09-17       Impact factor: 9.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.